Torben Fog - A Danish pioneer in a ...
Type de document :
Article dans une revue scientifique: Article original
PMID :
URL permanente :
Titre :
Torben Fog - A Danish pioneer in a multi-faceted spectrum of multiple sclerosis research.
Auteur(s) :
Sørensen, P. S. [Auteur]
University of Copenhagen = Københavns Universitet [UCPH]
Bramow, S. [Auteur]
Copenhagen University Hospital
Magyari, M. [Auteur]
Copenhagen University Hospital
Werdelin, L. [Auteur]
Koch-Henriksen, N. [Auteur]
Aarhus University Hospital
Vermersch, Patrick [Auteur]
Lille Neurosciences & Cognition (LilNCog) - U 1172
Sellebjerg, F. [Auteur]
Copenhagen University Hospital
University of Copenhagen = Københavns Universitet [UCPH]
Bramow, S. [Auteur]
Copenhagen University Hospital
Magyari, M. [Auteur]
Copenhagen University Hospital
Werdelin, L. [Auteur]
Koch-Henriksen, N. [Auteur]
Aarhus University Hospital
Vermersch, Patrick [Auteur]

Lille Neurosciences & Cognition (LilNCog) - U 1172
Sellebjerg, F. [Auteur]
Copenhagen University Hospital
Titre de la revue :
Mult Scler
Nom court de la revue :
Mult Scler
Pagination :
13524585241239506
Date de publication :
2024-03-26
ISSN :
1477-0970
Mot(s)-clé(s) en anglais :
Multiple sclerosis
disease modifying therapies
clinical trial
multiple sclerosis pathology
disease modifying therapies
clinical trial
multiple sclerosis pathology
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Torben Fog was committed to multiple sclerosis (MS) research for more than four decades, starting before the defence of his thesis in 1948 and lasting until his death in 1987. His research was multi-facetted, making him ...
Lire la suite >Torben Fog was committed to multiple sclerosis (MS) research for more than four decades, starting before the defence of his thesis in 1948 and lasting until his death in 1987. His research was multi-facetted, making him one of the great pioneers in the study of essential parts of the pathology, immunology and treatment of MS. He has contributed with meticulous studies of the MS plaques, documenting the perivenous distribution of plaques in the spinal cord. He constructed a scoring system for the disability in MS and used a computer programme to calculate a total neurological deficit. Together with his co-workers, Fog in 1972 was the first to report the association between MS and the human leukocyte antigen system. Fog can be considered as the father of immunomodulatory therapy in MS, treating MS patients with the first transfer factor, and as early as 1980, he was the first to treat MS with intramuscular natural interferon.Lire moins >
Lire la suite >Torben Fog was committed to multiple sclerosis (MS) research for more than four decades, starting before the defence of his thesis in 1948 and lasting until his death in 1987. His research was multi-facetted, making him one of the great pioneers in the study of essential parts of the pathology, immunology and treatment of MS. He has contributed with meticulous studies of the MS plaques, documenting the perivenous distribution of plaques in the spinal cord. He constructed a scoring system for the disability in MS and used a computer programme to calculate a total neurological deficit. Together with his co-workers, Fog in 1972 was the first to report the association between MS and the human leukocyte antigen system. Fog can be considered as the father of immunomodulatory therapy in MS, treating MS patients with the first transfer factor, and as early as 1980, he was the first to treat MS with intramuscular natural interferon.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Université de Lille
Inserm
CHU Lille
Inserm
CHU Lille
Collections :
Équipe(s) de recherche :
Neuroinflammation & Multiple Sclerosis (NEMESIS)
Date de dépôt :
2024-05-06T22:39:23Z
2024-12-04T09:58:08Z
2024-12-04T09:58:08Z